MapLight Therapeutics, Inc.

NASDAQ:MPLT

Biotechnology

Healthcare
$6.65 +3.11%

+$0.39 today

Market cap
$283.41M
Beta
2.65
P/E (TTM)
-2.8
EPS (TTM)
-$4.41
52W Low $9.10High $40.43

Volume 0.42M

Average 0.73M

MPLT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

MapLight Therapeutics, Inc.NASDAQ: MPLT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $162K fell 2.4% year over year, ahead of the -20.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.7% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.4% holds above the trailing-twelve-month pace of -20.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$162K+15.7% QoQ
Last fiscal yearDec 2025
$578K-17.5% YoY
LTMMar 2026
$574K-20.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year-17.5%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
578K USD
Year-over-year change
-17.5%
3-year CAGR
+0.2%

Depreciation & Amortization vs competitors

How MPLT compares with its peers on the latest reported figures

  • MPLT's LTM Mar 2026 depreciation & amortization of $574K is the 4th largest of the 11 companies compared; the peer median is $246.75K.
  • Its year-over-year change of -20.3% is the 4th highest of 8, against a peer median of -57.2%.
  • Over three fiscal years its annual growth of +0.2% compares with a peer median of +77.5%.
MPLT Competitors Peer median
Depreciation & Amortization for MPLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$2.77M -57.2%+62.5%2.3%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M +7.4%+296.1%5.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$674K +14.4%+24.6%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$574K -20.3%+0.2%—
GHRSGH Research PLCLTM Mar 2026$350K +12.5%+92.4%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$325.5K —+443.4%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$168K -72.2%-41.8%2.4%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$59K -90.6%-29.5%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$2.72K —+761.4%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$0 -100.0%——
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 ———
Peer median (excluding MPLT) $246.75K-57.2%+77.5%2.4%

Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.02M)(55.71M)(77.58M)(161.15M)
Depreciation & Amortization574K556K701K578K
Deferred Income Tax0000
Stock-Based Compensation0000
Change in Working Capital1.72M2.04M(3.07M)(12.84M)
Accounts Receivables0000
Inventory0000
Accounts Payables0000
Other Working Capital1.72M2.04M(3.07M)(12.84M)
Other Non-Cash Items1.14M1.11M1.13M35.27M
Operating Cash Flow(26.58M)(52.01M)(78.82M)(138.14M)
Capital Expenditures(746K)(462K)(770K)(473K)
Acquisitions (Net)0000
Purchases of Investments00(125.02M)(408.23M)
Sales of Investments0045M85.5M
Other Investing Activities0000
Investing Cash Flow(746K)(462K)(80.79M)(323.21M)
Debt Repayment0000
Common Stock Issued33.17M104.57M120.25M474.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities33.18M104.57M(2.19M)(5.02M)
Financing Cash Flow33.17M104.57M118.06M469.82M
Effect of Forex Changes21.81M027K0
Net Change in Cash27.67M52.1M(41.52M)8.48M
Free Cash Flow(27.32M)(52.47M)(79.59M)(138.61M)

MapLight Therapeutics, Inc.

NASDAQ:MPLT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.